protein tyrosine phosphatase receptor type FGenealiases: BNAH2 · LAR
Q-omics provides the consensus-scored PTPRF profile across patient tissues and cancer cell-line models. PTPRF expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PTPRF is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, PTPRF protein abundance shows 20,751 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where PTPRF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRF survival associations across molecular data types. PTPRF RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRF RNA expression–survival associations across cancer types. High PTPRF expression shows unfavorable associations in ACC, LGG, LIHC, SKCM, KIRP and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PTPRF RNA expression.
This table summarizes PTPRF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PTPRF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRF shows lower tumor expression in COAD and higher tumor expression in LUSC, LIHC, BLCA, HNSC and CHOL. The COAD box plot shows higher PTPRF RNA expression in normal versus tumor tissue (log2 FC = −0.886, t-test p < 0.001).
This table shows molecular features associated with PTPRF in patient tissues and cancer cell lines. In patient samples, PTPRF shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
